The impact of Brexit on the pharmaceutical sector Contents



1 Introduction

The pharmaceutical sector

Our inquiry

2 Tariff barriers

Impact of No Deal

3 Non-tariff barriers

Border delays

Other non-tariff barriers

4 Regulatory alignment

Approval of Medicines

EU Medicines Approval Procedures

Manufacturing and Testing

Opportunities from divergence

Future Relationship

European Court of Justice

The Future of the European Medicines Agency

5 Transitional Arrangements

6 Trade opportunities post-Brexit

Intellectual Property

7 Skills

8 Research and Development

Clinical Trials

9 Conclusion

Conclusions and recommendations

Formal minutes


Published written evidence

List of Reports from the Committee during the current Parliament

Published: 17 May 2018